RedHill Biopharma Launches Talicia In UAE to Combat H. pylori Infections

RedHill Biopharma Ltd. has introduced Talicia, a combination drug (omeprazole magnesium, amoxicillin, and rifabutin), in the United Arab Emirates (UAE). Now available by prescription, Talicia is aimed at treating adults with Helicobacter pylori (H. pylori) infection, a bacterium linked to stomach ulcers and an increased risk of stomach cancer.

This launch in the UAE also opens the door for RedHill to receive milestone payments, guaranteed sales payments, and tiered royalties of up to mid-teens based on net sales. Talicia stands out as the first approved combination treatment in the UAE that includes low-dose rifabutin specifically designed to fight H. pylori.

Rick Scruggs, President, RedHill Biopharma Inc. & Chief Commercial Officer said, "We are delighted with the commercial launch of Talicia in the UAE, bringing this important medicine to patients in the region. As one of the strongest risk factors for gastric cancer, H. pylori is a major public health concern. With 41% of the UAE population infected by H. pylori and the alarming failure rates of clarithromycin-based therapies, there is a significant medical need for a highly effective first-line H. pylori therapy. Our efforts to make Talicia available to patients in more countries continue as we work to explore additional opportunities with existing and potential partners.”